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A 28 year-old woman presented to the Ophthalmology Clinic at the Armed Forces Hospital, Muscat, Oman, with 
severe pain, redness, photophobia and decrease 
in visual acuity of her left eye of 1 day’s duration. 
She gave a history of a pterygium excision with 
intraoperative topical mitomycin-C application 
(0.1 mg/ml for 5 minutes ) in the same eye two 
years before. There was no other systemic or local 
disease. She underwent a detailed ophthalmic and 
systemic evaluation and laboratory examination. 
The best corrected visual acuity in her right eye 
was -0.25sph/-0.50cyl /90 = 6/6 and in the left eye 
-0.25sph/-1cyl 140 = 6/12. Her left eye showed 
conjunctival and ciliary congestion. There was a 
linear ulcer on the cornea about 2 mm from the 
nasal limbus with a scar immediately temporal to 
it. There was no surrounding infiltration, but the 
nasal 4–5mm of cornea was thin between  6 and 11 
o’clock [Figures 1a and 1b] The adjacent sclera was 
normal. The intraocular pressure and fundus of both 
the eyes was normal. Scrapings and swabs from the 
ulcer base were sent for microbiological evaluation. 
The left eye was treated with prophylactic antibiotic 
drops and artificial tears. The ulcer responded to 
treatment in a period of 4 weeks, leaving a thin 
nasal cornea with peripheral limbal vascularisation 
[Figure 2].
Pterygium is an epithelial hyperplasia 
accompanied by a fibrovascular growth originating 
at the corneo-conjunctival junction, from where 
the modified limbic cells migrate and surpass 
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INTERESTING MEDICAL IMAGE
Figure 1a: Left eye – corneal ulcer 2mm from the nasal 
limbus.
Figure 1b: Left eye – corneal scar temporal to ulcer.
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the cornea. It is an active process associated 
with cell growth, remodelling of the connective 
tissue, angiogenesis and inflammation, triggered 
by ultraviolet irradiation. Different investigators 
have recently emphasised the importance of the 
limbus and its stem cells in the pathogenesis of the 
pterygium.1,2 Surgery as a treatment for pterygium 
has been known since 1,000 B.C and has been 
directed towards excision, prevention of recurrence, 
and restoration of ocular surface integrity. The 
recurrence rate has, in the past, been estimated 
as high as 30–70%, despite adoption of different 
evolutionary techniques.1,2,3 Although irradiation 
therapy and antimetabolite use have diminished 
the recurrence rate to 5–12%, complications like 
secondary glaucoma, cataracts, uveitis, corneal 
perforation, scleritis, scleral necrosis and secondary 
endophthalmitis can occur.1-5 Mitomycin, isolated 
from Streptomyces caespitosus, is an extremely 
toxic, non cell-specific alkylating antibiotic with 
antineoplastic properties that selectively inhibits 
the synthesis of  deoxyribonucleic acid (DNA), 
ribonucleinc acid (RNA) and protein, and prevents 
cellular division.1-3 The DNA damage mimics 
that of ionising radiation and has a radiomimetic 
effect. The drug has been used in the eye since 
1963 for its anti-fibroblast proliferating action, in 
pterygium and glaucoma surgeries and recently in 
refractive procedures, both for the management of 
certain complications and to improve vision after 
surgery.1-5 However, in susceptible individuals, 
it  causes keratocyte depletion leading to delayed 
wound healing, irrespective of the technique 
of application.1-5 Complications occur either 
immediately after surgery, or up to 20 years later, 
and are related to drug concentration, contact time 
and predisposing ocular factors, highlighting the 
fact that such patients need long term follow-up.3,4,5
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Figure 2: Left eye – 4 weeks after treatment showing no 
corneal stain/ healed ulcer.
